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Nonalcoholic steatohepatitis (NASH), along with
other forms of nonalcoholic fatty liver disease, is an
increasingly common clinico-pathological syndrome. It
is frequently associated with obesity, especially visceral
fat, and type 2 diabetes, and is intimately related to
markers of the insulin resistance syndrome. Both the
prevalence and the severity of liver steatosis are related
to body mass index, waist circumference, hyper-
insulinaemia, hypertriglyceridaemia and impaired glu-
cose tolerance. The pathophysiology of NASH involves
two steps : 1) insulin resistance, which causes steatosis;
2) and oxidative stress, which produces lipid
peroxidation and activates inflammatory cytokines. The
identification of subjects who may progress from fatty
liver to NASH, and from NASH to fibrosis/cirrhosis is
an important clinical challenge as well as the finding of
appropriate therapy that could prevent such deleterious
process. Substantial weight loss is accompanied by a
marked attenuation of insulin resistance and related
metabolic syndrome and, concomitantly, by an impor-
tant regression of liver steatosis in most patients, al-
though mild inflammation may be detected in some sub-
jects. Thus, NASH may be considered as another dis-
ease of affluence, as is the insulin resistance syndrome
and perhaps being part of it.
INTRODUCTION
The spectrum of nonalcoholic fatty liver disease
(NAFLD) is broad from steatosis and nonalcoholic
steatohepatitis (NASH) through to cirrhosis and liver
failure (1-6). The term NASH was coined in 1980 to
describe “the pathological and clinical features of non-
alcoholic disease of the liver associated with the patho-
logical features most commonly seen in alcoholic liver
disease itself” (7). The role of obesity and type 2 diabe-
tes appears to be crucial (8,9) so that NASH is now con-
sidered as “another disease of affluence” (10). Perhaps
of most concern is the recent observations that NAFLD
and NASH may also be observed in children and ado-
lescents (11). The increasing prevalence and severity of
obesity (12) has heightened concerns about the frequency
of the progression of NASH to end-stage liver disease
(13). While in patients with fatty liver only, long-term
follow-up suggests a benign, non-progressive course,
advanced NASH may differ substantially in prognosis
and lead to obvious fibrosis and cryptogenic cirrhosis
Editorial
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(review in 5,9).
 The present review aims at discussing the role of
insulin resistance and related metabolic abnormalities
in the development of NAFLD in general, and NASH
in particular. Better understanding of etiopathogenesis
and pathophysiology of such liver disease may stimu-
late new perspectives for successful therapeutic inter-
ventions.
ETIOPATHOGENESIS OF NASH
As recently reviewed (14), the etiopathogenesis of
NASH appears multifactorial. It has been recently dem-
onstrated that peripheral insulin resistance, increased
fatty acid beta-oxidation, and hepatic oxidative stress
are present in both fatty liver and NASH, but NASH
alone is associated with mitochondrial structural defects
(15). A “two hit” hypothesis has been proposed whereby
the first “hit”, i.e. steatosis, sensitises the liver to a vari-
ety of second “hits” which lead to necroinflammation
and fibrosis (16) (Figure 1). With regard to the first hit,
insulin resistance, compensatory hyperinsulinaemia and
increased free fatty acid (FFA) supply to the liver seem
to play a major role. In most subjects, it is related to
obesity and abdominal fat distribution, various features
of the metabolic syndrome, and sometimes overt type 2
diabetes mellitus (see below). The principal candidates
for the second hit are abnormal cytokine production and
oxidative stress.
a) Role of free fatty acids and insulin resistance
The crucial role of increased FFA levels in the
pathogenesis of insulin resistance has been extensively
reviewed (17). In addition, increased influx of FFA to
the liver combined with potential alterations in their
hepatic metabolism (including increased triglyceride
synthesis, decreased triglyceride export, or decreased
fatty acid oxidation) may result in hepatic steatosis (18).
Any defect of this multistep process results in accumu-
lation of triglyceride within the hepatocyte. Whether this
process is responsible for the subsequent inflammatory
cell infiltration characteristic of NASH or whether an
inflammatory response in the liver evoked by some other
stimulus causes sufficient hepatocyte dysfunction to re-
sult in steatosis has not been established yet (19).
As already suggested by a pioneer work published
as early as 1950 (20), diabetic patients with fatty liver
are remarkably insensitive to insulin. Insulin resistance,
Figure 1 : Insulin resistance initiating the development of steatosis and NASH
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together with compensatory hyperinsulinaemia, is a com-
mon feature in obesity (21,22). Insulin plays a key role
in the regulation of regional FFA metabolism and can
inhibit hepatic mitochondrial beta-oxidation of FFA (23).
Visceral fat mass is a predictor of both insulin resist-
ance and steatosis (24). Visceral lipolysis is resistant to
insulin suppression and is the source of liver fatty acids
in insulin resistance and hyperinsulinaemic states such
a liver disease (23). Conversely, fatty liver may influ-
ence insulin clearance and insulin resistance, a process
which can initiate a vicious circle (25). Thus, the con-
junction of high FFA and insulin resistance, both directly
related to increased (visceral) fat mass (see below), is
crucial for the development of liver steatosis.
b) Role of cytokines, leptin and TNF-a
It has been recently suggested that the high circulat-
ing leptin levels associated with obesity (26) may con-
tribute to hepatic steatosis (27). Serum leptin levels are
significantly higher in patients with NASH (28), and
this elevation is out of proportion to BMI (29). These
observations led to the hypothesis that elevated serum
leptin levels may promote hepatic steatosis and
steatohepatitis. However, the precise role of leptin re-
mains to be elucidated as animal studies suggested that
a physiological role of hyperleptinaemia resulting from
caloric excess may be to protect nonadipocyte cells (in-
cluding hepatocytes) from steatosis and lipotoxicity (30).
Finally, given the similar intracellular signaling path-
ways stimulated by leptin and several inflammatory
cytokines (27), leptin may also be involved in the pro-
gression from hepatic steatosis to steatohepatitis, and
possibly fibrosis (31).
Cytokines, especially tumour necrosis factor alpha
(TNF-α), have also been incriminated in the
pathogenesis of NASH (review in 14,32). As TNF-α is
overexpressed in adipose tissue of obese subjects and in
overweight patients with type 2 diabetes, resulting in
higher circulating TNF-α levels (33), its role should be
further investigated in the pathogenesis of NASH asso-
ciated with obesity and/or diabetes. In favour of this
hypothesis, a recent study suggested that TNF-α
polymorphisms could represent a susceptibility geno-
type for insulin resistance, NAFLD, and NASH (34).
Finally, bacterial overgrowth of the small intestine could
also contribute to raised TNF-α in patients with NASH
(35). Thus, it has been recently hypothesized that the
egress of products from intestinal bacteria into the por-
tal blood, liver, and systemic circulation may trigger a
sustained inflammatory cytokine response in genetically
susceptible individuals that may contribute to both
NASH and insulin resistance (36).
c) Role of oxydative stress and iron accumulation
Oxidative stress may play a prominent role in NASH.
An increase in mitochondrial reactive oxygen species
production seems likely to be a response to an increased
hepatic supply of FFA, resulting in a compensatory in-
crease in the rate of mitochondrial beta oxidation (15).
Lipid peroxidation products alter mitochondrial DNA
and also react with mitochondrial proteins to inhibit the
transfer of electrons along the respiratory chain, further
increasing reactive oxygen species production and re-
sulting in a self perpetuating cycle of oxydative stress
and lipid peroxidation (37). Other potential sources of
oxidative stress that have been suggested to play a role
in NASH include an increase in liver iron (14). Recent
observations showed that elevated serum ferritin and iron
levels are common findings in patients with NASH and
insulin resistance, even in absence of haemochromato-
sis (38,39), and one study reported that increased he-
patic iron had the greatest association with the severity
of liver fibrosis (40).
ASSOCIATION OF NASH WITH OBESITY
AND TYPE 2 DIABETES
As recently reviewed (8,9), obesity is the condition
most often associated with NAFLD. In a literature sur-
vey of 41 original articles comprising information on
liver morphology in 1,515 morbidly obese patients, liver
biopsy was considered as normal in only 12 % of the
cases (41). The most frequent abnormality reported was
fatty changes present in 80 % of the biopsies; portal in-
flammation was also common (33 %) while portal or
periportal fibrosis was observed in 29 %. Cirrhosis, how-
ever, involved only 3 % of the biopsies. Two large se-
ries of liver biposies performed in more than 500 se-
verely obese subjects submitted to bariatric surgery have
been recentlty published. In 551 liver biopsies, steato-
sis was found in 86 %, fibrosis in 74 %, mild inflamma-
tion or steatohepatitis in 24 %, and unexpected cirrho-
sis in 2 % of the patients (42). In a large personal series
of 528 severely obese subjects (BMI 42.6 ± 6.8 kg/m2),
74 % of the biopsies showed fatty deposition, estimated
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as mild in 41 % of cases, moderate in 32 % and severe
in 27 % (43). The severity of steatosis was positively
associated with BMI (p = 0.002) (8). Ten % of these
patients had signs of steatohepatitis, inflammatory
changes being scored as mild in 86 %, moderate in 12
% and severe in 2 % of cases. In contrast, fibrosis and
cirrhosis were rather rare (around 3 %).
Besides obesity, elevated blood glucose values have
been noted in 34 % to 75 % of patients with NAFLD
(review in 1,8,9,36). In type 2 diabetic patients over age
60, the prevalence of fatty liver has been reported to be
about 45 % (review in 8,16). The association between
type 2 diabetes and NASH seems to be strong, varying
from 2 % to 50 % in various studies (14). The role of
diabetes in producing more severe liver pathology ap-
pears controversial although “diabetic hepatitis” has been
recognized as a pathological entity (44). Some (45), but
not all (46), studies suggested that diabetes is a strong
independent predictor of severe hepatic fibrosis in
NASH.
Thus, type 2 diabetes is strongly associated with
NAFLD. At present, however, it is not clear if one of
these conditions causes the other, or if both are the con-
sequences of another process (review in 36,47).
NASH AS A FEATURE OF THE INSULIN
RESISTANCE SYNDROME
Syndromes are clusters of non-chance associations,
and the components of a syndrome can generally be re-
lated to a common element. In insulin resistance syn-
drome, central fat accumulation (truncal or abdominal/
visceral), impaired glucose metabolism (or overt type 2
diabetes), raised blood pressure (or clinical hyper-
tension), and dyslipidaemia (typically, hyper-
triglyceridaemia, low HDL cholesterol, high levels of
small dense LDL, and postprandial hyperlipidaemia)
cluster with insulin resistance, as indicated by a low to-
tal-body insulin-mediated glucose disposal (48-50).
Because of its simplicity, fasting hyperinsulinaemia is
the most commonly used surrogate for insulin resist-
ance. Hyperinsulinaemia has been long recognized in
hepatic steatosis, irrespective of weight excess, and fatty
liver has been considered to be associated with relative
insulin resistance to which elevated FFA may contrib-
ute (51,52). Several recent studies reported that both
peripheral and hepatic insulin resistance are present in
almost all patients with NAFLD, irrespective of the co-
existence of obesity or impaired glucose tolerance
(15,53,54). Genetic predisposition that reduces insulin
sensitivity and increases serum triglyceride levels may
be responsible for its development (53). Besides obes-
ity, hyperlipidaemia has been reported in 20 % to 81 %
of patients with NASH (review in 1). Importantly, pa-
tients with NASH are more insulin resistant than pa-
tients with fatty liver alone (15,34,54-58) and than pa-
tients with chronic hepatitis C virus (58). NAFLD, in
the presence of normoglycaemia and normal or moder-
ately increased body weight, is characterized by clini-
cal and laboratory data similar to those found in diabe-
tes and obesity. Thus, NAFLD may be considered an
additional feature of the metabolic syndrome, with spe-
cific hepatic insulin resistance (57,59,60).
Viseral fat is strongly associated with insulin resist-
ance and related metabolic disorders characterizing the
metabolic syndrome or syndrome X (61,62). It has been
shown that abdominal distribution of fat is a predictor
of hepatic steatosis, which is independent of body weight
and body fat (63). In type 2 diabetic men, liver fat score
was highly correlated to visceral/total adipose tissue
ratio, insulin resistance and serum triglyceride levels
(51). In a series of 48 consecutive patients with NAFLD,
most subjects (81 %) were overweight or obese and had
increased waist circumference, which closely relates to
visceral fat and insulin resistance (60). In NAFLD
subjects with normal body weight, a waist-to-hip ratio
similar to that of overweight subjects and significantly
larger than that of normal subjects has been reported
(54). NAFLD was also linked to insulin resistance in
normal weight Korean subjects, a population known to
have increased visceral adiposity in the presence of nor-
mal body weight (64). In a recent paediatric study on
375 obese children and adolescents, liver steatosis was
present in 33 % to 47 % of the subjects according to the
Tanner pubertal stages (11). Again, in this particular
population, liver steatosis was more closely related to
waist to hip ratio, an index of central obesity, than to
BMI. One study reported that surgical removal of vis-
ceral fat reverses hepatic insulin resistance (65). Thus,
all these observations suggest a key role of visceral adi-
posity in the development of both insulin resistance and
NAFLD. The link between abdominal obesity and liver
injury may be explained, especially when resistance to
antilipolytic action of insulin is present (23), by the fact
that fatty acids are mobilized more rapidly from vis-
ceral (central) than from subcutaneous (peripheral) fat
and drained directly to the liver via the portal vein (61).
Marceau et al (41) reported on the frequent associa-
tion between the metabolic syndrome observed in se-
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vere obesity and liver pathology in 551 liver biopsies
performed during anti-obesity surgery. With each addi-
tion of 1 of the 4 following components of the meta-
bolic syndrome (elevated waist/hip ratio, impaired glu-
cose tolerance, hypertension, and dyslipidaemia), the risk
of steatosis increased exponentially from 1- to 99-fold
(p < 0.001). In a large series of 505 severely obese sub-
jects evaluated before gastroplasty, we estimated vari-
ous biological parameters classically associated with the
insulin resistance syndrome (66), and we attempted to
correlate such biological abnormalities with both the
presence and the severity of steatosis (42). When com-
pared with patients without fatty liver deposition, those
with liver steatosis had significantly higher fasting
plasma glucose, insulin, triglyceride and aminoalanine
transferase (ALT) levels. The severity of the steatosis
was positively correlated, not only to BMI (p = 0.002),
but also to fasting plasma glucose, insulin and triglyce-
ride concentrations as well as to serum liver enzyme
levels (Fig 2). Similar observations suggesting a close
relationship between NAFLD and NASH in obese sub-
jects with various features of the insulin resistance syn-
drome were reported in smaller series. Among 105 con-
secutive patients submitted to laparoscopic obesity sur-
gery, 26 patients were found to have NASH and 11 of
these advanced fibrosis (55). In this study, a raised in-
dex of insulin resistance and systemic hypertension,
another feature of the metabolic syndrome, were inde-
pendent predictors of NASH. In a retrospective review
of 90 patients with NASH, insulin resistance was present
in almost all subjects (85 %), as well as various compo-
nents of the metabolic syndrome such as diabetes, hy-
perlipidaemia, hypertension and atherosclerotic disease
(67). In 30 patients with NAFLD, obesity was present
in 80 % of patients, hypertension in 50 % and diabetes
in 33 %. In addition, glucose metabolism was altered in
above two thirds of the patients, with elevated insulin
levels in about half (59).
The relationship between insulin resistance, iron
overload and liver disease has been recently discussed
(37,38). Among 65 patients with a new clinical-patho-
logical syndrome of primary hepatic iron overload (in
Figure 2 : Relationships between the degree of steatosis (grade 0 : no steatosis; grade 1 : mild steatosis; grade 2 : moderate steatosis; grade 3 :
severe steatosis) and the prevalence (%) of high levels of three markers of insulin resistance (fasting plasma glucose, plasma insulin, and serum
triglycerides) and of three serum liver enzymes (ALT, AST and gamma-GT) in a large cohort of severely obese subjects (references 8 and 43).
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absence of haemochromatosis), 72 % had a BMI greater
than 25 kg/m2, 65 % were dyslipidaemic, and 43 % had
abnormal glucose tolearance, i.e. there was a high fre-
quency of some of the features of the insulin resistance
syndrome (68). In a subsequent study of 161 patients,
the patients with unexplained hepatic iron overload,
mostly middle-aged men, had a high rate of insulin re-
sistance syndrome (94 %) (69). In this study, hepatic
steatosis was found in 50 % of patients with unexplained
hepatic iron overload plus at least one of the compo-
nents of the insulin resistance syndrome including
truncal obesity, type 2 diabetes mellitus, and
hypertriglyceridaemia. Individuals with high ferritin le-
vels and hepatic iron overload associated with insulin
resistance can have symptom relief after venesection
(70). In 17 patients with moderate obesity, impaired glu-
cose tolerance and clinical evidence of NAFLD, iron
depletion by phlebotomy was associated with signifi-
cant reduction of fasting and stimulated insulin levels
(in agreement with a reduction of insulin resistance) and,
concomitantly, a near-normalization of serum
aminoalanine transferase (ALT) activity, suggesting a
key role of iron and hyperinsulinaemia in the
pathogenesis of NAFLD (71).
THERAPEUTIC APPROACHES OF NASH
Besides various specific pharmacological approaches
(review in 36,72), treatment of patients with NASH has
typically been focused on the management of associ-
ated conditions such as obesity, diabetes mellitus, and
hyperlipidaemia, although it is not always effective in
reversing NASH (60,73,74). Specific treatment of
NASH may be important as NASH is now considered
the starting point for most “cryptogenic” cirrhosis (75).
a) Pharmacological interventions targeting insulin
resistance
Owing the close relationship between insulin resist-
ance and NAFLD/NASH, it is reasonable to speculate
that the use of medications that improve insulin sensi-
tivity may benefit the liver disease, especially in pres-
ence of obesity and type 2 diabetes (76). It has been
shown that metformin reverses fatty liver disease in
obese, leptin-deficient mice (77). In 20 patients with
NASH, four months of metformin treatment led to a re-
duction in serum transaminase (which were normalized
in 50 % of cases) and liver volume compared with no
changes in non-compliant patients (78). These prelimi-
nary results should be urgently confirmed in a
randomised controlled trial.
Thiazolidinediones are a new class of antidiabetic
drugs. They selectively enhance insulin action on glu-
cose metabolism, more in the skeletal muscle than in
the liver. The resulting antihyperglycaemic effect is fre-
quently accompanied by a reduction in circulating con-
centrations of insulin, triglycerides and FFA (79). Nor-
malization of ALT levels was seen in 7 of 10 patients
with NASH at the end of a treatment with troglitazone
for several months (80). However, this biochemical re-
sponse was associated with only mild histological im-
provement, and all follow-up biopsies had still evidence
of NASH. It should be noted that troglitazone has been
withdrawn because of severe hepatotoxicity. Fortunately,
other thiazolidinedione agents, like rosiglitazone and
pioglitazone, do not share this hepatotoxicity, and anec-
dotal reductions of ALT levels in patients with initial
elevation of liver enzymes have been reported in clini-
cal trials with type 2 diabetic patients (81). Indeed, poorly
controlled patients with type 2 diabetes may have mod-
erate elevations of serum ALT that will decrease with
improved glycaemic control during treatment with
glitazone (82). These observations deserve further evalu-
ation in NAFLD patients.
b) Reversibility after weight loss
Because obesity is the most common phenotype as-
sociated with NASH, it seems paradoxical that more
florid forms of the disorder were initially recognized
after operations designed to achieve weight reduction,
especially jejuno-ileal bypass (JIB) surgery (1,14,71).
The spectrum of hepatic disease following JIB includes
steatosis, steatohepatitis, progressive fibrosis leading to
cirrhosis, and liver failure that may be fatal (83,84).
Steatohepatitis often develops during the period of maxi-
mum weight loss, but the risk of liver fibrosis increases
with the duration of follow-up (85). The pathogenesis
of NASH after JIB in morbidly obese patients appears
to be multifactorial : potential mechanisms include mas-
sive mobilization of FFAs during initial weight loss,
severe protein malnutrition and resorption of bacterial
toxins from the defunctionalized intestine (14). Thus,
after NASH was encountered as a common and severe
complication of JIB for morbid obesity during the 1970s,
this approach was abandoned (1,14,71) and replaced by
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other surgical procedures that do not share such liver
complications, i.e. gastroplasty and gastric bypass (86).
Numerous studies showed that weight loss is accom-
panied by a significant improvement of insulin sensi-
tivity in obese patients. As an example, a full normali-
zation of the abnormalities in insulin secretion, clear-
ance and action on glucose metabolism could be de-
monstrated in severely obese patients who recovered an
ideal body weight after gastroplasty (87). However, the
effect of weight loss on liver disease is not consistent as
recently reviewed by our group (8,9). Early studies al-
ready demonstrated that weight reduction due to fasting
or low calorie diets are associated with reduced steato-
sis, but that a transient increase in the degree of hepato-
cellular degeneration and focal necrosis may also occur
(88).
In most reports, favourable results have been reported
after other forms of anti-obesity surgical procedures than
JIP. In a series of 91 patients followed from 2 to 61
months after gastric bypass with gastrojejunostomy, liver
biopsies showed that 65 patients had reduced steatosis;
pre-gastric bypass biopsies showed perisinusoidal fibro-
sis in 13 patients which disappeared afterwards in 10
patients (89). Of our large cohort of severely obese sub-
jects submitted to a gastroplasty (vertical-ring
gastroplasty or adjustable banding), 69 patients had a
second liver biopsy 27 ± 15 months after initial surgery
(42). After a mean weight loss of 32 ± 19 kg, a remark-
able reduction in liver fatty scores was observed (Table
1). Such regression of steatosis was observed even in
absence of weight normalization. Interestingly, it oc-
curred concomitantly with the regression of various fea-
tures of the insulin resistance syndrome (8,66,90,91).
Indeed, a remarkable improvement in the biological
markers of the metabolic syndrome was observed in 505
obese patients after a mean follow-up of 26 ± 14 months
and a mean weight loss of 32 ± 16 kg after gastroplasty
(Table 2) (66). Insulin resistance index (87) and
hyperleptinaemia (8) were also markedly reduced after
weight loss. All these hormonal and metabolic improve-
ments related to weight reduction should favourably
influence NAFLD of obese subjects. However, a slight
but significant increase in the prevalence of hepatitis
was observed after pronounced weight reduction (26 %
of the biopsies after gastroplasty versus 14 % before, p
< 0.05) (42). Our results thus confirm those obtained in
another study in which a rapid weight loss of 34 ± 9 kg
with a very-low-calorie formula diet resulted in a sig-
nificant improvement of fatty change, but 24 % of the
patients developed slight portal inflammation or fibro-
sis (92). Considering the potential deleterious effect of
FFA (16,19), these data may suggest that the rapid mo-
bilization of lipid stores induced by drastic weight loss
may be toxic for the liver and result in mild lobular hepa-
titis in some patients.
TABLE 1 : Prevalence (%) of abnormal liver biopsies in a subgroup of 69 obese subjects before and 27 ±
15 months after gastroplasty and a substantial weight loss of 32 ± 19 kg (adapted from reference 43).
Before After
Parameters weight loss weight loss p
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CONCLUSIONS
Liver steatosis is a common feature in patients with
visceral adiposity and diabetic status. Although it is of-
ten considered as a benign disease, it may progress in
some patients to steatohepatitis and cryptogenic cirrho-
sis. NAFLD and NASH are strongly associated with
insulin resistance and classical biological markers of the
metabolic syndrome. Drastic weight loss results in a sig-
nificant improvement of both insulin sensitivity and bio-
logical abnormalities of the metabolic syndrome. In a
parallel fashion, a marked reduction in both the preva-
lence and the severity of liver steatosis was observed
but, in some cases, at the expense of mild steatohepatitis.
Growing evidence leads to the concept that NASH is
intimately linked to insulin resistance. Thus, NASH
should be considered as being part of the insulin resist-
ance syndrome and, consequently, as an interface for
gastroenterologists and endocrinologists.
RÉSUMÉ
La stéatohépatite non alcolique (NASH) est une
maladie de mieux en mieux individualisée qui suscite
un vif intérêt depuis quelques années. Elle est
fréquemment associée à l’obésité, spécialement à
l’adiposité viscérale, et au diabète de type 2; elle est
intimement liée à la stéatose et à divers marqueurs du
syndrome d’insulinorésistance. La prévalence et la
sévérité de la stéatose sont corrélées à l’indice de masse
corporelle, à la circonférence de la taille, à
l’hyperinsulinémie, à l’hypertriglyceridémie et à la dimi-
nution de la tolérance au glucose. La physiopathologie
de la NASH impliquerait deux processus : 1)
l’insulinorésistance, à l’origine de la stéatose; 2) et le
stress oxydatif, responsable d’une peroxydation lipidique
et d’une activation de cytokines inflammatoires.
L’identification des sujets obèses qui vont progresser
de la stéatose vers la NASH et de la NASH vers la fi-
brose ou la cirrhose constitue un défi clinique majeur,
tout comme la découverte de traitements susceptibles
d’empêcher cette évolution délétère. Une perte de poids
importante est accompagnée par une réduction marquée
de l’insulinorésistance et du syndrome métabolique
associé et, concomitamment, par une régression de la
stéatose hépatique chez la plupart des patients, même si
une légère inflammation péri-hépatocytaire est observée
chez certains sujets. Ainsi, la NASH peut être considérée
comme une autre maladie de l’affluence, tout comme le
syndrome d’insulinorésistance et, sans doute, fait partie
intégrante de celui-ci.
TABLE 2 : Prevalence (%) of abnormal biological values related to the metabolic syndrome in 505 obese
subjects before and 26 ± 14 months after gastroplasty and a substantial weight loss of 32 ± 16 kg (adapted
from reference 66).
Before After
Parameters weight loss weight loss p
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